Retatrutide activates three receptors GLP-1, GIP, and glucagon while tirzepatide activates two (GLP-1 and GIP)
The data does not support this approach well
Tesamorelin is usually discussed in a different context, especially growth-hormone signalling and visceral-fat research
Semaglutide, a selective GLP-1 receptor agonist marketed as Ozempic, Wegovy, and Rybelsus, is one of the most extensively studied anti-obesity and anti-diabetes medications in history, with over 25,000 clinical trial participants and FDA approval for three distinct indications
Connecting with others on similar journeys often makes the difference between success and discontinuation
Others notice increased sweating during exercise